Dr. Dino PratoEnvita Medical Centers · Founder and CEO at Envita Medical Centers

youtube shorts the truth about breast cancer recurrence SUBBED

27 Apr 2026 · 1 min

Watch on YouTube

0:49

In this short monologue, Dr. Dino Prato reflects on the emotional moment when a woman finishes breast‑cancer treatment, only to face the lingering fear of recurrence. He cites that about 30 % of early‑stage breast cancers (stage 0‑I) eventually return, and that risk climbs sharply for higher‑stage disease (stage II‑IV). Dr. Prato criticizes the current “one‑size‑fits‑all” surveillance model that relies on a handful of tumor markers, occasional biopsies, and limited next‑generation sequencing that yields only a few hundred genetic markers. He argues for “deep precision testing” that examines 1,000 + markers, enabling a personalized immune‑based strategy and the use of immunotherapy to better prevent or treat recurrence.

Chapters

A woman finishes treatment for breast cancer. She walks in and rings a bell and she hopes it's all over. Everybody claps. The family and friends are really excited and they have a party. The cancer's gone. And then there's like a pause. What if this cancer shows up again? Do I have a plan? What if it comes back? Because in 30% of breast cancer diagnoses, early stage breast cancers can come back with recurrence. If you're dealing with that higher risk breast cancer, that's now stage 2, 3, 4, it's spread already. You don't want to be stuck in the one-size-fits-all model of just 24 markers, a tumor marker, biopsy, and imaging, and maybe a next-generation sequence DNA marker gives you a few hundred markers. You want 1,000+ markers. The secret here is deep precision testing. In my clinical experience, it gives you a custom immune strategy. That's the key. Immunotherapy.